Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.

× No keyword cloud information.

9 in total

1. Liposomes as vehicles for cellular incorporation of biologically active macromolecules.

Authors: D Paphadjopoulos; T Wilson; R Taber
Journal: In Vitro Date: 1980-01

2. Liposomes in chemo- and immunotherapy of cancer.

Authors: G L Scherphof; T Daemen; H H Spanjer; F H Roerdink
Journal: Lipids Date: 1987-11 Impact factor: 1.880

Review 3. Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Authors: Lindsay A M Rein; David A Rizzieri
Journal: Ther Adv Hematol Date: 2014-12

Review 4. Clinical pharmacokinetics of cytarabine formulations.

Authors: Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal: Clin Pharmacokinet Date: 2002 Impact factor: 6.447

5. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

Authors: A Trouet; M Masquelier; R Baurain; D Deprez-De Campeneere
Journal: Proc Natl Acad Sci U S A Date: 1982-01 Impact factor: 11.205

6. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors: P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal: Cancer Chemother Pharmacol Date: 1988 Impact factor: 3.333

Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-beta-D-arabinofuranosylcytosine against mouse L1210 leukemia.

1. Liposomes as vehicles for cellular incorporation of biologically active macromolecules.

2. Liposomes in chemo- and immunotherapy of cancer.

Review 3. Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Review 4. Clinical pharmacokinetics of cytarabine formulations.

5. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies.

6. Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Review 7. Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

8. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.

9. Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.